44 The clot thickens: identifying risk factors for VTE in metastatic and recurrent cervical cancer
Cervical cancer (CC) patients infer a greater risk for venous thromboembolism (VTE) than the general population. r/mCC patients with VTE are at high risk of adverse bleeding events on therapeutic anticoagulation. There are no reliable risk stratification tools to identify patients who would benefit...
Saved in:
| Published in: | Gynecologic oncology reports 2023-08, Vol.48, p.S23-S23 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | eng |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Cervical cancer (CC) patients infer a greater risk for venous thromboembolism (VTE) than the general population. r/mCC patients with VTE are at high risk of adverse bleeding events on therapeutic anticoagulation. There are no reliable risk stratification tools to identify patients who would benefit from thromboprophylaxis. We previously showed Khorana score was not effective at predicting VTE risk. This study aims to correlate other commonly known risk factors with VTE risk in patients with recurrent or metastatic cervical cancer (r/mCC).
We performed a retrospective review of patients at an urban university system diagnosed with r/mCC receiving systemic chemotherapy between 2010 and 2021. Clinical and demographic information was abstracted from the medical record, with special attention to known VTE risk factors. Exclusion criteria were diagnosis with more than one cancer, previous VTE, unverified pathology, or inadequate follow-up. Statistical analysis was performed using Chi square, Fisher exact, and logistic regression.
285 patients were identified, and 194 were included in the final analysis. 144 (74.4%) received treatment for recurrent disease, and 50 (25.6%) received systemic treatment for stage IVB disease. The mean age was 49, and the majority (59.2%) had BMI |
|---|---|
| ISSN: | 2352-5789 2352-5789 |